Policy Developments - Shenzhen has issued measures to support the development of innovative drugs and medical devices, focusing on areas such as nucleic acid drugs, protein and peptide drugs, cell drugs, and small molecule innovative drugs, with a total of 32 specific measures proposed [1] Drug Approvals - Eli Lilly's application for the new drug imlunestrant, a selective estrogen receptor degrader for treating ER+ and HER2- advanced breast cancer, has been accepted by China's National Medical Products Administration [2] - Heng Rui Medicine's SHR0302 (aimatinib), a JAK1 inhibitor, has received approval for a new indication for treating moderate to severe atopic dermatitis in adults and adolescents aged 12 and above [3] Capital Market Activities - Kehua Bio has signed an investment cooperation agreement to establish a medical device and testing reagent production base and an innovation center in Xi'an, covering approximately 90 acres [4] - TianKang Bio plans to introduce external investors through a capital increase, with two investors subscribing to a total of RMB 27.5 million for new registered capital [6] Research and Development - Innovent Biologics has announced that its tumor pipeline products ICP-248, ICP-723, and ICP-B05 have been selected for presentation at the 2025 ASCO Annual Meeting [5] - Pian Zai Huang has signed a technology transfer contract worth RMB 13.58 million for a new traditional Chinese medicine, which aligns with the trend of innovation in the TCM industry [8] Financial Reports - Sunshine Nuohua reported a revenue of RMB 1.078 billion for 2024, a year-on-year increase of 15.7%, but a net profit of RMB 177 million, down 3.98% [9] - David Medical's revenue for 2024 was RMB 527.03 million, a decrease of 14.76%, with a net profit decline of 61.21% [10] - Bai O Tai reported a revenue of RMB 743 million for 2024, a 5.44% increase, but a net loss of RMB 510 million, compared to a loss of RMB 395 million in the previous year [11]

Key Points - The Federal Reserve's Goolsbee expressed concerns that tariffs may reignite inflation fears among businesses [2] - U.S. Treasury Secretary Yellen stated that President Trump will personally engage in trade negotiations [2] - Reports indicate that President Trump will sign an executive order on Tuesday to support the coal industry [2] Company News - Broadcom (AVGO.O) announced a $10 billion stock buyback plan [2] - United Microelectronics Corp (UMC.N) reported a 9.31% year-over-year revenue increase to NT$198.6 billion for March [2] - Moomoo Inc. has received approval from the China Securities Regulatory Commission for its IPO in the U.S., planning to issue approximately 64.22 million shares [2] - Eli Lilly (LLY.N) has had its application for a new drug, imlunestrant tablets, accepted in China for breast cancer treatment [2] - Apple (AAPL.O) staff reported a surge in panic buying of Apple products over the past weekend [2] - General Motors (GM.N) unveiled a new electric Corvette concept car, reaffirming its commitment to the European market [2] - Micron Technology (MU.O) informed U.S. customers that it will impose additional fees related to tariffs on certain products starting April 9 [2] - UnitedHealth Group (UNH.N) saw a 5% increase in after-hours trading, as the Trump administration plans to significantly raise Medicare payment rates next year [2]